Basilea targets Swiss exchange

Swiss biopharmaceutical company Basilea Pharmaceutica has announced plans to list on the SWX Swiss Exchange through an initial public offering later this month. The timing of the launch is still subject to market conditions.

Credit Suisse First Boston and Morgan Stanley have been appointed joint global coordinators and joint bookrunners for the offering, with Swissfirst also participating in the syndicate.

Basilea has a broad development portfolio with its lead compounds poised to enter phase II-III. The company secured expansion financing from HBM BioVentures at the end of 2001. The planned public offering will provide additional financial resources to enable the company to continue its growth.